ADC Therapeutics SA Sales And Marketing Expense
ADC Therapeutics SA (ADCT) reported Sales And Marketing Expense of $13.73 million for the 3-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:SalesAndMarketingExpense · last filed 2023-11-07
- ADC Therapeutics SA sales and marketing expense for the quarter ending 2023-09-30 was $13.73M, a 18.50% decline year-over-year.
- ADC Therapeutics SA sales and marketing expense for the quarter ending 2023-06-30 was $14.46M, a 18.14% decline year-over-year.
- ADC Therapeutics SA sales and marketing expense for the quarter ending 2023-03-31 was $15.35M, a 16.43% decline year-over-year.
- ADC Therapeutics SA sales and marketing expense for the quarter ending 2022-12-31 was $16.18M, a 13.05% decline year-over-year.
| Period end | Sales And Marketing Expense 3 month | Sales And Marketing Expense 6 month | Sales And Marketing Expense 9 month | Sales And Marketing Expense 12 month |
|---|---|---|---|---|
| 2023-09-30 | $13.73M 6-K · filed 2023-11-07 | $28.19M derived: sum of 2 quarters · filed 2023-11-07 | $43.54M 6-K · filed 2023-11-07 | $59.71M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $14.46M 6-K · filed 2023-08-08 | $29.81M 6-K · filed 2023-08-08 | $45.98M derived: sum of 3 quarters · filed 2023-08-08 | $62.83M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | $15.35M 6-K · filed 2023-05-09 | $31.53M derived: sum of 2 quarters · filed 2023-05-09 | $48.37M derived: sum of 3 quarters · filed 2023-11-07 | $66.03M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | $16.18M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $33.02M derived: sum of 2 quarters · filed 2023-11-07 | $50.68M derived: sum of 3 quarters · filed 2023-11-07 | $69.05M 20-F · filed 2023-03-15 |
| 2022-09-30 | $16.85M 6-K · filed 2023-11-07 | $34.51M derived: sum of 2 quarters · filed 2023-11-07 | $52.88M 6-K · filed 2023-11-07 | $71.48M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $17.66M 6-K · filed 2023-08-08 | $36.03M 6-K · filed 2023-08-08 | $54.63M derived: sum of 3 quarters · filed 2023-08-08 | $71.68M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $18.37M 6-K · filed 2023-05-09 | $36.97M derived: sum of 2 quarters · filed 2023-05-09 | $54.02M derived: sum of 3 quarters · filed 2023-05-09 | $69.24M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $18.60M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $35.65M derived: sum of 2 quarters · filed 2023-03-15 | $50.87M derived: sum of 3 quarters · filed 2023-03-15 | $64.78M 20-F · filed 2023-03-15 |
| 2021-09-30 | $17.05M 6-K · filed 2022-11-08 | $32.27M derived: sum of 2 quarters · filed 2022-11-08 | $46.18M 6-K · filed 2022-11-08 | $55.53M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $15.22M 6-K · filed 2022-08-09 | $29.13M 6-K · filed 2022-08-09 | $38.48M derived: sum of 3 quarters · filed 2023-03-15 | $44.60M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $13.91M 6-K · filed 2022-05-09 | $23.26M derived: sum of 2 quarters · filed 2023-03-15 | $29.38M derived: sum of 3 quarters · filed 2023-03-15 | $33.38M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $9.35M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $15.47M derived: sum of 2 quarters · filed 2023-03-15 | $19.47M derived: sum of 3 quarters · filed 2023-03-15 | $22.10M 20-F · filed 2023-03-15 |
| 2020-09-30 | $6.12M 6-K · filed 2021-11-02 | $10.12M derived: sum of 2 quarters · filed 2021-11-02 | $12.75M 6-K · filed 2021-11-02 | |
| 2020-06-30 | $4.00M 6-K · filed 2021-08-03 | $6.63M 6-K · filed 2021-08-03 | ||
| 2020-03-31 | $2.63M 6-K · filed 2021-05-06 | |||
| 2019-12-31 | $0.00 20-F · filed 2022-03-17 | |||
| 2018-12-31 | $0.00 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |